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St Louis, MO, USAA B S T R A C TObjective: In spite of increases in short-term kidney transplant
survival rates and reductions in acute rejection rates, increasing
long-term graft survival rates remains a major challenge. The objec-
tive here was to project long-term graft- and survival-related out-
comes occurring among renal transplant recipients based on short-
term outcomes including acute rejection and estimated glomerular
ﬁltration rates observed in randomized trials. Methods: We devel-
oped a two-phase decision model including a trial phase and a Markov
state transition phase to project long-term outcomes over the life-
times of hypothetical renal graft recipients who survived the trial
period with a functioning graft. Health states included functioning
graft stratiﬁed by level of renal function, failed graft, functioning
regraft, and death. Transitions between health states were predicted
using statistical models that accounted for renal function, acute
rejection, and new-onset diabetes after transplant and for donor
and recipient predictors of long-term graft and patient survival.
Models were estimated using data from 38,015 renal transplantsee front matter Copyright & 2014, International S
r Inc.
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Halifax, NS, Canada B3H 1V7.recipients from the United States Renal Data System. The model
was populated with data from a 3-year, randomized phase III trial
comparing belatacept to cyclosporine. Results: The decision model
was well calibrated with data from the United States Renal Data
System. Long-term extrapolation of Belatacept Evaluation of Neph-
roprotection and Efﬁcacy as Firstline Immunosuppression Trial was
projected to yield a 1.9-year increase in time alive with a functioning
graft and a 1.2 life-year increase over a 20-year time horizon.
Conclusions: This is the ﬁrst long-term follow-up model of renal trans-
plant patients to be based on renal function, acute rejection, and new-
onset diabetes. It is a useful tool for undertaking comparative effective-
ness and cost-effectiveness studies of immunosuppressive medications.
Keywords: decision model, end stage renal disease, modeling, renal
transplant.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rapid increases in the incidence of end-stage renal disease and
aging of the population in industrialized countries are leading to
growing numbers of individuals requiring lifelong renal replace-
ment therapy and a greater call on limited health care resources
for this condition. In the United States, the incidence of end-stage
renal disease doubled between 1998 and 2008, from 183 to 351 per
million population [1]. Renal transplantation offers substantial
beneﬁts over long-term dialysis [2] and is the treatment of choice
for end-stage renal disease [3]. The number of persons with end-
stage renal disease being placed on US wait lists for kidney
transplantation continues to grow each year, with approximately
99,250 candidates registered as of December 2013 [4].
The success of renal transplantation has arisen in large
measure as a result of the efﬁcacy of immunosuppressive
medications. Early trials in kidney transplantation from the
1970s demonstrated that azathioprine and prednisone were
efﬁcacious for immunosuppression, leading to improvements inthe end points of graft and patient survival [5,6]. The introduction
of cyclosporine in 1978 led to the use of acute rejection as the
primary trial end point [7–14] because graft failure and death
became too rare to design realistically sized trials within reason-
able periods of observation.
In spite of reductions in acute rejection [15], long-term renal
graft and patient survival have not improved, and transplant
researchers are shifting focus to other surrogates as end points
[16]. For instance, renal functioning at 1 year posttransplant has
been shown to be associated with long-term graft and patient
survival [17–20] and new-onset diabetes is known to be a major
complication after kidney transplant [21].
Most published decision models of immunosuppressive med-
ications in kidney transplant are based primarily on associations
between acute rejection and graft and patient survival. Although
episodes of acute rejection can have deleterious consequences to
the patient, be costly to treat, and increase the risk of graft
failure, acute rejection alone is not a reliable predictor of long-
term outcomes [22]. The speciﬁc objective of this study is toociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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transplant distributions of renal function, acute rejection, and
new-onset diabetes at the end of follow-up in randomized trials
to estimate the effect of immunosuppressant therapy on graft
and patient survival among renal transplant recipients in the
United States.Methods
Model Structure and Outputs
The decision model includes two phases (Fig. 1). Phase 1, the
“trial period,” incorporates renal functioning (categorical esti-
mated glomerular ﬁltration rates [eGFRs] measured in mL/min/
1.73 m2) and the probabilities of experiencing unintended and
undesirable outcomes at the end of follow-up of a randomized
trial: new-onset diabetes, acute rejection, graft failure, and death.
It is assumed that individuals with an eGFR of less than 15 mL/
min/1.73 m2 are in the graft failure state.
Phase 2, the “extrapolation period,” incorporates a Markov
model to reﬂect 20-year follow-up of hypothetical individuals
surviving the trial period with a functioning graft. Markov models
are used widely in the health economic modeling of disease and
represent a reasonable compromise between simplicity on the
one hand, which aids transparency and understanding of the
model, and ﬂexibility on the other, which allows key aspects of
the disease course and treatment pathways to be captured [23].
Starting with the distribution of functioning graft health states,
subjects experience declining eGFR over time [24–26], progressing
in 1-year cycles. At the end of each cycle, subjects can 1) remain(re
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Fig. 1 – Schematic of the decision model for extrapolating long-te
eGFR, estimated glomerular ﬁltration rate; NODM, new-onset dia
of renal functioning deﬁned by the US National Kidney Foundatio
than or equal to 45 and less than 60; 3b ¼ eGFR greater than or eq
to 15 and less than 30.in the same state, 2) experience graft failure and return to
hemodialysis, or 3) move to the absorbing death state. Patients
are categorized at the end of the trial period into one of four
categories of renal functioning deﬁned by the US National Kidney
Foundation [27]: eGFR greater than or equal to 60, eGFR greater
than or equal to 45 and less than 60, eGFR greater than or equal to
30 and less than 45, and eGFR greater than or equal to 15 and less
than 30. While in the functioning graft health states, eGFR is
assumed to decline linearly until graft failure occurs at an eGFR of
less than 15 mL/min/1.73m2. Following graft failure, individuals
remain in the hemodialysis state until death or regraft. A regraft
health state is included because the third most common cause
for being placed on a wait list in the United States is a previously
failed transplant [28]. Following a regraft, individuals reenter into
an undifferentiated functioning graft state and the time to graft
failure or death is based on an exponential distribution.
The Markov model is run separately for each functioning graft
health state, and the outcome measures are weighted by the
observational eGFR distribution from the trial period and
summed to obtain results. This allows ﬂexibility because the
model can be used to project results from other studies by
incorporating information on relevant parameters from those
studies. The number of life-years spent in each graft functioning
health state is calculated once a subject enters the graft failure
state by allocating life-years assuming that eGFR declines linearly
over time starting at the entry health state and transitioning
through subsequent health states stopping at an eGFR of 15. The
time spent in each functioning graft health state is weighted by a
utility to obtain quality-adjusted life-years.
Outcomes output by model include cumulative proportions
alive with a functioning graft, time alive with a functioning graft,Funconing
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rm outcomes after renal transplantation. AR, acute rejection;
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n [27]: 2 ¼ eGFR greater than or equal to 60; 3a ¼ eGFR greater
ual to 30 and less than 45; and 4 ¼ eGFR greater than or equal
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grammed in Microsoft EXCEL using visual basic macros and is
fully parameterized, allowing different values of model parame-
ters and one-way and probabilistic sensitivity analyses [29].
Model veriﬁcation included testing for internal consistency using
extensive debugging and testing extreme conditions and calibra-
tion against the source data (i.e., United States Renal Data System
[USRDS]) [30].
Data Sources
Information for the model is derived from three sources. 1) All
trial period outcomes from the Belatacept Evaluation of Neph-
roprotection and Efﬁcacy as Firstline Immunosuppression Trial
(BENEFIT) [31] were reported at 3 years (see Appendix Table,
Table 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2014.01.001) except new-onset diabetes and the distri-
butions in patients 3a and 3b, which were not reported in the
publication. New-onset diabetes incidence was taken from the 2-
year published results [32], while eGFR stage 3 was assumed to be
evenly distributed between patients 3a and 3b. 2) Data for
processes used to derive transition probabilities in the Markov
model as well as donor and recipient characteristics of transplant
patient populations not available from the phase III trial pub-
lished data are from the USRDS. The USRDS is a national data
system available for researchers and is made up of multiple
component registries of organ donors and recipients in the
United States [33]. The historical development, structure, and
limitations of the data for research purposes are well described
[34,35]. The USRDS makes available data on the occurrence,
clinical characteristics, treatment, mortality, and survival rate
of transplant recipients. This study included all kidney transplant
recipients listed in the USRDS of deceased donor, single-organ
transplants between 1995 and 2003, and who had Medicare as the
primary payer for their transplant care. Medicare was the insurer
for at least 66% of adult patients included in the USRDS between
April 1995 and December 2004. The models are based on 38,015
recipients who had functioning grafts and on whom estimated
eGFR could be calculated on day 366 posttransplant. Measure-
ments of eGFR are reported annually. The list of candidate
demographic and clinical variables available for use come from
a published model on long-term outcomes in kidney transplant
[36]. 3) Utilities for each eGFR category were from a study of 386
kidney transplant recipients aged 18 to 74 years treated in two
Midwestern outpatient clinics who completed the Health Utilities
Index Mark III questionnaire [37]. The utilities are as follows: 0.70
for eGFR greater than or equal to 60, 0.63 for eGFR greater than or
equal to 45 and less than 60, 0.63 for eGFR greater than or equal to
30 and less than 45, 0.62 for eGFR greater than or equal to 15 and
less than 30, and 0.59 for eGFR less than 15 [38]. The utility with a
functioning regraft was assumed to be the arithmetic mean
utility of functioning eGFR categories [38].
Renal functioning was characterized using eGFR because it is a
more accurate measure than serum creatinine [27]. The eGFR was
computed according to the abbreviated Modiﬁcation of Diet in Renal
Disease equation [39] as follows: eGFR (mL/min/1.73 m2) ¼ 186 
(Serum Creatinine mg/dL)  1.154  Age  0.203  (1.212, if African-
American)  (0.742, if Female). The abbreviated Modiﬁcation of Diet
in Renal Disease equation has been validated as a measure of renal
functioning among kidney transplant recipients [40].
Transition Probabilities
The transition probabilities in the extrapolation period are derived
from a series of processes that are modeled using different types of
parametric regression models ﬁt using USRDS data (Appendix table
in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2014.01.001) [41]. For those subjects entering the extrapolation
period, the annual probabilities of experiencing graft failure or
death, respectively, are estimated using Weibull models. These
models are parametric regression models, which allow extrapola-
tion beyond the period of observation and allow the likelihood of a
transition to change with time under observation [42]. Once the
graft fails, the time spent in the dialysis health state is calculated
using an exponential model because the Markov assumption does
not allow the transition probability of this health state to depend on
the timing of graft failure [43]. The USRDS data did not include
information describing new-onset diabetes, and the effect of new-
onset diabetes on graft failure and death, respectively, was incorpo-
rated into the model via published hazard ratios [21].
Target Population
The target population is US Medicare-covered kidney transplant
recipients. The statistical models are based on a historical cohort
of patients receiving organs from deceased donors and treated
predominantly with calcineurin-inhibitor–based immunosup-
pression [44]. To account for the observation that eGFR decline
was slower in 2003 than in 1995, a variable for calendar year was
included in the published models.
Treatments
In this case, the treatments included were cyclosporine (any
formulation) and belatacept (Nulojix). The two immunosuppres-
sants were compared directly in BENEFIT, a 3-year, randomized,
active-controlled, parallel-group, multicenter phase III study
conducted at 100 centers worldwide, enrolling standard criteria
donors [31,45]. Belatacept received approval from the US Food
and Drug Administration on June 15, 2011, to prevent acute
rejection in adult patients who have had a kidney transplant.
Sensitivity Analysis
Stochastic distributions were applied to uncertain parameters,
allowing for results to be varied in a probabilistic sensitivity
analysis. The variability was based on observed variability in trial
outcomes [31,45] and regression equation coefﬁcients [44].Results
The Appendix Table in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2014.01.001 shows the risk equations in
the underlying Markov model predicting graft and patient sur-
vival modeled in the extrapolation phase using the data from the
USRDS. In addition to regression coefﬁcients, hazard ratios
associated with new-onset diabetes were 1.46 for death-
censored graft failure and 1.87 for death [21]. The probabilities
describing the transitions from an initial functioning graft to graft
failure or death were dependent on time and stratiﬁed by eGFR at
1 year posttransplant and are displayed in Figure 2A,B. The
probabilities over time for graft failure and death were inversely
related to eGFR category, although minimal differences in sur-
vival probabilities were observed across the two highest eGFR
categories. The regression equations for death were censored by
graft failure, and as such do not represent the probability of
overall mortality but rather the probability of mortality condi-
tional on having a functioning graft. As shown in Figure 2A, the
long-term probability of having a functioning graft decreased
sharply after 20 years, and the subsequent mortality probabilities
were relevant only to the minority of individuals remaining in the
functioning graft state.
Transition probabilities estimated via exponential equations
can be summarized by a single time-invariant probability: the
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Fig. 2 – Results of combined 1 to 3 year and 4þ year Weibull time-to-event equations describing (A) probability of initial graft
failure beginning 1 year posttransplant and (B) probability of death (with censoring at time of graft failure), based on estimated
glomerular ﬁltration rate (mL/min/1.73m2) at 3 years posttransplantation in BENEFIT [47]. BENEFIT, Belatacept Evaluation of
Nephroprotection and Efﬁcacy as Firstline Immunosuppression Trial; GFR, glomerular ﬁltration rate.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 5 4 – 2 6 0 257annual probability of transitioning from dialysis to retransplan-
tation was 0.04; the annual probability of dying while on dialysis
was 0.12; the annual probability of experiencing graft failure with
a functioning regraft was 0.10; and the annual probability of
dying with a functioning regraft was 0.06.
Among graft recipients in BENEFIT, demographic and baseline
characteristics were well balanced between groups and comparable
to US population [46]. The mean age was 43 years, and 70% were
men. At 3 years posttransplant, a higher proportion of patients in
the cyclosporine group had died or suffered graft failure than in the
belatacept group, while a higher proportion of patients in the
belatacept group had acute rejection, most of which occurred in
the ﬁrst 6 months posttransplant (Table 1). Themean eGFR was 21.4
mL/min/1.73 m2 higher in the belatacept group, yielding a distribu-
tion of eGFR categories shifted to the higher functioning categories.
The calibration of the decision model was done by comparing
the model-predicted survival to Kaplan-Meier survival curves ﬁt
to USRDS data over the ﬁrst 5 years posttransplant (Fig. 3).
Because of the large number of individuals included within the
USRDS (n ¼ 38,015), the 95% CIs for Kaplan-Meier USRDS-pre-
dicted survival display little variability, with upper and lower
bounds within 2% of each other throughout the 5-year period. For
the ﬁrst 3 years, model-predicted survival is within 0.5% of theupper bound of the 95% CI and in the ﬁnal 2 years, model-
predicted survival falls between the 95% CI bounds. The existing,
relatively minor, discrepancies are likely due to deviations in
continuous covariates from the normal distribution.
Using the transition probabilities derived from the USRDS
equations, the long-term extrapolation phase of the model
indicated that the difference in the proportions of recipients
suffering graft failure and having a regraft was lower in the
belatacept group at all points in time (data not shown). The
differences at 3 years in eGFR are projected to avert graft failure
(57% cumulative graft failures projected for the belatacept group
relative to 65% for the cyclosporine group over 20 years) and yield
2.5 incremental years alive with a functioning graft (95% empiri-
cal CI 1.3–3.4), a 10.1% increase in patients surviving over a 20-
year time horizon, and a corresponding incremental 1.5 life-years
(95% CI 0.9–1.9) and 1.2 quality-adjusted life-years (95% CI 0.8–
1.6). Of the time alive with a functioning graft, a greater propor-
tion of time, for example, 46% (5.2 years of 11.4 with a functioning
graft) for belatacept versus 22% (2.0 years of 8.9 with a function-
ing graft) for cyclosporine, was projected to be spent with renal
functioning of 60 mL or more.
At every point in time, the cumulative proportions of individ-
uals with a functioning graft (Fig. 4 and Table 2) and which
Table 1 – Clinical outcomes and distributions of
eGFR (mL/min/1.73m2) at 4 y posttransplantation
among graft recipients randomized to receive
cyclosporine or belatacept (less intensive regimen)
in BENEFIT [47].
Cyclosporine
(n ¼ 221)
Belatacept
(n ¼ 226)
Recipients surviving with
functioning graft and GFR
Z 15 (%)
73.7 82.6
Death (%) 6.8 4.4
Graft loss (%) 19.5 12.3
Acute rejection (%) 10.0 17.0
New-onset diabetes (%) 11.0 5.0
Mean eGFR  SD 44.4  23.6 65.8  27.0
Distribution of eGFR at 3 y
posttransplant (%)
29.0 71.0
Z60 25.0 10.0
Z45 and o60 25.0 10.0
Z30 and o45 6.0 0.0
Z15 and o30 15.0 9.0
o15
BENEFIT, Belatacept Evaluation of Nephroprotection and Efﬁcacy
as Firstline Immunosuppression Trial; eGFR, estimated glomerular
ﬁltration rate.
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http://dx.doi.org/10.1016/j.jval.2014.01.001) are higher among per-
sons receiving belatacept than cyclosporine.Discussion
In the coming years, novel immunosuppressive medications may
offer the possibility of preserving renal function [45]. Character-
izing the therapeutic value of these medications, in terms of
either comparative effectiveness or incremental cost-effective-
ness, will require long-term projections of graft and patient
survival. The model described in this article permits the lifetime
extrapolation of long-term outcomes given any distribution ofFig. 3 – Five-year survival observed within the United States Re
survival.eGFR categories, acute rejection, and new-onset diabetes. The
model incorporates important demographic and clinical charac-
teristics of recipients during the early posttransplant trial period
that can affect graft- and survival-related outcomes. It can be
extended in a straightforward fashion to include longer trial
durations and include other immunosuppressive medications
including existing agents such as tacrolimus and sirolimus, or
novel agents under development. Sufﬁcient information is pro-
vided to allow other investigators to recreate the model using
standard software (e.g., Microsoft EXCEL and Treeage).
Extensive veriﬁcation processes demonstrate that inputs and
outputs of this model are consistent with known facts regarding
renal transplant. Given the high precision of the Kaplan-Meier
analysis (Fig. 3), the level of consistency between the two sets of
curves provides considerable assurance that the model is well
calibrated. In the future, the model’s validity may be tested with
longer-term follow-up of the trial populations. The probabilistic
structure of the model is strength insofar as it allows statistical
comparisons of projections to observed ﬁndings [30].
A published two-stage literature-based model has been used
to estimate the economic impact among kidney transplant
recipients with lower renal function by one measure of renal
function, serum creatinine [47]. The current model is an impor-
tant step forward in that: it uses renal functioning expressed as
eGFR; transition probabilities are based on primary data analysis
using outcomes data on actual transplant recipients; and impor-
tant predictors of graft and patient survival, such as acute
rejection in the trial period and new-onset diabetes, are included.
More generally, predicting long-term outcomes from inter-
mediate end points is often of interest to clinicians and research-
ers. Except in rare circumstances such as those provided by the
Framingham studies, models that incorporate both trial data and
long-term follow-up are required [48]. The current model applies
those techniques using high-quality data from the USRDS regis-
try. This application serves as an example for decision models in
other areas of surgery.
Important limitations exist regarding the model, including
those related to the structure and data inputs. There are at least
ﬁve structural features of the model that may have an important
impact on the results and interpretations. First, the underlying
premise of the model is that early survival of patients with higher
renal functioning predicts late survival. While current evidence
indicates that this premise is correct [17–20], longer follow-up of
observational cohorts will provide a better characterization of thenal Data System compared with model-predicted 5-year
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Fig. 4 – Projected cumulative proportion of individuals during long-term extrapolation period alive with a functioning graft
based on estimated glomerular ﬁltration rate (mL/min/1.73m2) at 3 years posttransplantation in BENEFIT [46]. BENEFIT,
Belatacept Evaluation of Nephroprotection and Efﬁcacy as Firstline Immunosuppression Trial.
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in the trial period. If the separation in GFR between the treatment
groups continues to increase beyond that which was observed in
the 3-year follow-up period in BENEFIT [31], the long-term
estimates of clinical beneﬁt projected here may represent the
lower limit of incremental beneﬁt for new treatments. Third,
posttransplant eGFR is assumed to reach its zenith at 3 years and
then decline equally in both groups. In months 3 to 36 of BENEFIT
III, the mean calculated eGFR increased in the belatacept arms by
þ1.0 mL/min/1.73 m2/y (more intensive regimen) and þ1.2 mL/
min/1.73 m2/y (less intensive regimen) versus a decline of 2.0
mL/min/1.73 m2/y in the cyclosporine arm [31]. Fourth, in the
functioning graft health state, subjects are allowed to stay only in
the same eGFR category or a lower one. The results are likely to
be robust to minor violations of this assumption because subjects
are grouped into eGFR categories. Fourth, the variables includedTable 2 – Projected 20-y (95% CI) absolute and
incremental graft- and survival-related outcomes
based on eGFR at 3 y posttransplantation in BENEFIT
[46].
Cyclosporine
point estimate
Belatacept
point estimate
Time spent (y)
Functioning graft 8.9 11.4
eGFR stage 2 (Z60) 2.0 5.2
eGFR stage 3a
(Z45 and o60)
2.4 2.6
eGFR stage 3b
(Z30 and o45)
2.7 2.3
eGFR stage 4
(Z15 and o30)
1.8 1.3
Graft failure/dialysis 4.1 3.2
Retransplant 0.6 0.5
Life-years (95% CI) 13.6 (11.8–14.7) 15.1 (13.0–16.0)
QALYs (95% CI) 8.5 (7.3–9.3) 9.7 (8.2–10.5)
BENEFIT, Belatacept Evaluation of Nephroprotection and Efﬁcacy
as Firstline Immunosuppression Trial; eGFR, estimated glomerular
ﬁltration rate; QALY, quality-adjusted life-year.in the predictive models are limited to those available in the
USRDS. Because new-onset diabetes following transplant is
known to have a large impact on long-term outcomes [49], it
was included using other published information [21]. There may
be other potential confounders, however, which are not included.Conclusions
This is the ﬁrst long-term follow-up model of renal transplant
patients to be based on graft function, acute rejection, and new-
onset diabetes and can incorporate data from clinical trials of
newly approved treatments in renal transplant. It is a useful tool
for undertaking comparative effectiveness studies of new immu-
nosuppressive medications. By incorporating resource utilization
and costs, it can also be used to carry out methodologically sound
economic evaluations in renal transplant.Acknowledgments
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